qtr-two adjusted non-gaap earnings per share $num-one.
qtr-two revenue $num-one billion versus refinitiv ibes estimate of $6.72 billion.
for qtr-three year-six, anticipates that non-gaap core revenue growth will be in mid- to high-teens percent range.
for full year year-six, now anticipates that non-gaap core revenue growth rate including cytiva will be about num-two%.
for full year year-six, now anticipates that non-gaap core revenue growth rate including cytiva will be about num-four%.
for full year year-six, now anticipates that non-gaap core revenue growth rate including cytiva will be about num-one%.
for full year year-six, now anticipates that non-gaap core revenue growth rate including cytiva will be about num-one%.